ライフサイエンスコーパス: b.i.d.

1 Oral administration b.i.d. of R115777 to nude mice bearing s.c. tumors at do

2 reasing doses of morphine (5-25 mg/kg, s.c., b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7

3 ete forebrain 5-HT (D,L-FEN, 20 mg/kg, s.c., b.i.d.).

4 ing SCH66336 doses given orally twice a day (b.i.d.) for 7 days out of every 3 weeks.

5 r =2 hours before surgery, then twice a day (b.i.d.) until hospital discharge or for up to 7 days.

6 once daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d.

7 at doses of 237 micromol/kg/day twice a day (b.i.d.), there was serious proximal tubule damage versus

8 o 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidaz

9 (q.d.), 2.5-10 mg/kg of R-FB twice per day (b.i.d.), and 5 mg/kg of R-FB b.i.d. challenged with a hi

10 an-treated (5 days at 10 mg kg-1 bis in die (b.i.d.)) rats decreased renal blood flow by 46 and 29 %

11 or CEP-5214 to CD-1 mice at 23.8 mg/kg/dose b.i.d. resulted in a reversible inhibition of VEGF-R2/FL

12 p.o. of CEP-7055 at 2.57 to 23.8 mg/kg/dose b.i.d. resulted in dose-related reductions in neovascula

13 CEP-7055 at doses of 11.9 to 23.8 mg/kg/dose b.i.d. resulted in significant inhibition (50-90% maximu

14 twice per day (b.i.d.), and 5 mg/kg of R-FB b.i.d. challenged with a high saturated fat diet.

15 A dose of 5 mg/kg R-FB b.i.d. was able to overcome the doubling in tumor number

16 days with 10 mg/kg R-FB q.d. or 5 mg/kg R-FB b.i.d..

17 ther, we show that rifampin (75 or 100 mg/kg b.i.d. for 3 d, intraperitoneal) suppressed allodynia in

18 MPTP (24 mg/kg b.i.d. for 4 doses) increased striatal zif268 expression

19 models of contact hypersensitivity (1 mg/kg b.i.d.) and house dust (20 mg/kg q.d.) when dosed orally

20 decrease in weight gain observed at 36 mg/kg b.i.d.).

21 e at the time of transplantation was 5 mg/kg b.i.d.; doses were titrated to target trough levels.

22 ived either placebo or rhIGF-I (50 microg/kg b.i.d.) for 19 days in a randomized, double-blind, paral

23 administration of rhIGF-I (100 micrograms/kg b.i.d.) significantly lowered blood glucose.

24 c., b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7 days.

25 mer providing >99% inhibition at 12.5 mg/kg (b.i.d., orally) in the Leishmania infantum hamster model

26 vanserin (3 mg/kg), or haloperidol (1 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (d

27 (1 mg/kg) b.i.d. 30 min before PCP (2 mg/kg, b.i.d.) for 7 days (day1-7), followed by a 7-day washout

28 (A) receptor blockade (BMS 193884, 50 mg/kg, b.i.d.) for the last week of pacing; n=6; 3) CHF/ET(A)-L

29 ) receptor blockade (BMS 193884, 12.5 mg/kg, b.i.d.) for the last week, n=6; and 4) Control: n=8.

30 n mice when administered orally at 25 mg/kg, b.i.d., for 4 days.

31 ritoneal injection of TRK820 (0.1-10 mug/kg, b.i.d.) significantly inhibited tumor growth by suppress

32 cyclosporine microemulsion (Neoral) 60 mg/kg/b.i.d. on days +1 to +3 with dose adjusted by blood leve

33 /day) and either placebo or pindolol (5.0 mg b.i.d. or 2.5 mg t.i.d.), for 6 weeks, in a randomized,

34 ne, followed by maintenance on placebo (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

35 nd MMF dosing were 5 to 7 ng/mL and 1,000 mg b.i.d. in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d.

36 The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated do

37 posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonucleic acid was detected by RT

38 ences: sequence A (n = 15) Org 26576 (100 mg b.i.d.) for 3 weeks, followed by a 2-week placebo crosso

39 nicotinic receptor PAM JNJ-39393406 (100 mg b.i.d.) or placebo (double-blind, counter-balanced).

40 Org 26576 (100 mg b.i.d.) was superior to placebo in treating symptoms of

41 lacebo followed by 3 weeks Org 26576 (100 mg b.i.d.); sequence C (n = 18) Org 26576 flexible dose (10

42 al bleeding was lower with dabigatran 110 mg b.i.d. (aHR: 0.60, 95% CI: 0.37 to 0.93) compared with w

43 was seen with both dabigatran doses (110 mg b.i.d., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d.,

44 was lower with both dabigatran doses (110 mg b.i.d., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d.,

45 tly lower with both dabigatran doses (110 mg b.i.d., propensity-match group stratified hazard ratio [

46 .d., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg b.i.d., aHR: 0.08, 95% CI: 0.01 to 0.40).

47 .d., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d., aHR: 0.40, 95% CI: 0.21 to 0.70).

48 nfidence interval [CI]: 0.65 to 0.95; 150 mg b.i.d., aHR: 0.57, 95% CI: 0.40 to 0.80), when compared

49 ted to achieve glycemic control (< or =20 mg b.i.d. or q.d.).

50 either placebo capsules + AFS or LDD (20 mg b.i.d.) + AFS.

51 rofen (LDF) alone, 50 mg q.d.; 2) SDD (20 mg b.i.d.) alone; or 3) a combination of SDD plus LDF (comb

52 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.

53 ng sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients receiving placebo (N=19).

54 However, Org 26576 (100-300 mg b.i.d.) did not confirm these results.

55 (n = 18) Org 26576 flexible dose (100-300 mg b.i.d.) for 3 weeks, then 5 weeks placebo; sequence D (n

56 bo followed by 3 weeks Org 26576 (100-300 mg b.i.d.).

57 for future testing on this schedule (350 mg b.i.d.) but also provides the first evidence of successf

58 hree months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo pe

59 6) or placebo (n=2), the second cohort 40 mg b.i.d. (n=6) or placebo (n=2), and the third cohort 40 m

60 y on PPI and the dose was increased to 40 mg b.i.d. 31 consecutive patients with typical reflux sympt

61 nidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. cruzi deoxyribonuclei

62 ial human laboratory efficacy of IBUD (50 mg b.i.d.) on primary measures of subjective response to al

63 tes treated with either vildaglipitin (50 mg b.i.d.) or placebo for 10 days using a double-blind, pla

64 bo (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.).

65 . in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d. in group B.

66 One group received sodium naproxen 550 mg b.i.d. plus placebo for 7 days, while the other group re

67 other group received sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.

68 rapy with aerosolized colistin sodium (75 mg b.i.d.), and intravenous antibiotics were eliminated.

69 2 diabetic subjects taking metformin 850 mg b.i.d. versus placebo.

70 , dogs were treated with 30 mL of mouthrinse b.i.d. for 28 days.

71 q.d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET

72 ed 24 h after induction of MR (60 mg/kg p.o. b.i.d.) and continued for three months.

73 control received tacrolimus (0.15 mg/kg p.o. b.i.d.) and the same steroid taper.

74 1 g p.o. b.i.d.), tacrolimus (0.1 mg/kg p.o. b.i.d.), and a standard steroid taper.

75 ts in the study group received MMF (1 g p.o. b.i.d.), tacrolimus (0.1 mg/kg p.o. b.i.d.), and a stand

76 p.o. t.i.d.; n=19) or acyclovir (200 mg p.o. b.i.d.; n=23) was begun at transplantation and continued

77 Two doses of VEGFR2-TKI (25 mg/kg, p.o., b.i.d.) resulted in a decrease of V(b) to 1.3 +/- 0.3%.

78 aily postischemic oral dosing (1 mg/kg p.o., b.i.d., beginning at 1 h after insult) decreased the 28-

79 P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overe

80 atment with ganciclovir (GCV), 10 mg/kg i.p. b.i.d. for 6 days.

81 ts that had received cocaine (20 mg/kg, i.p. b.i.d.) or saline since birth.

82 d UCP-DTA mice with leptin (300 microg i.p., b.i.d.) and compared their response with that of leptin-

83 We tested the effect of LSF (100 mg/kg i.p., b.i.d.) on multilineage regeneration after high-dose 5-F

84 ob/ob and FVB control mice (30 microg i.p., b.i.d.).

85 day (b.i.d.); benznidazole 200 mg + placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg

86 ted with 40 mg pantoprazole (PPI) or placebo b.i.d. was performed.

87 arteether as controls, were administered po b.i.d. (128 mg/kg/day) to P. berghei-infected mice on da

88 dministered either CsA or CsA-ME at the same b.i.d. dosage as their maintenance therapy.